Daiwa Securities Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Daiwa Securities Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-73	Closed	-$10K	–	1304
2020 Q4	$10K	Sell	73 -139	-66%	-$12.3K	﹤0.01%	1019
2020 Q3	$11K	Hold	212	–	–	﹤0.01%	1036
2020 Q2	$10K	Hold	212	–	–	﹤0.01%	1070
2020 Q1	$10K	Hold	212	–	–	﹤0.01%	1061
2019 Q4	$12K	Sell	212 -22	-9%	-$1.09K	﹤0.01%	1048
2019 Q3	$8K	Hold	234	–	–	﹤0.01%	1047
2019 Q2	$7K	Hold	234	–	–	﹤0.01%	1078
2019 Q1	$5K	Sell	234 -116	-33%	-$1.86K	﹤0.01%	1088
2018 Q4	$5K	Buy	+350	New	+$4.42K	﹤0.01%	1067

Daiwa Securities Group's EIDX Position: Q1 2021 in Review

Daiwa Securities Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 73 shares — an estimated $10K sold.

Daiwa Securities Group first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $12K in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Daiwa Securities Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Daiwa Securities Group sold 73 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $10K.
Daiwa Securities Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Daiwa Securities Group's Eidos Therapeutics, Inc. Common Stock position peaked at $12K in Q4 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Daiwa Securities Group's 13F filing for Q1 2021, filed 3 May 2021.